ECOR Stock Risk & Deep Value Analysis
electroCore, Inc.
Healthcare • Medical Devices
DVR Score
out of 10
What You Need to Know About ECOR Stock
We analyzed electroCore, Inc. using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran ECOR through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
ECOR Risk Analysis & Red Flags
What Could Go Wrong
The company's cash balance of $11.6 million (Dec 31, 2025) is insufficient to cover its annual GAAP net loss of $14.0 million. This implies an imminent need for significant capital raising which will likely result in substantial shareholder dilution, depressing the stock price even if operational improvements continue.
Risk Matrix
Overall
Aggressive
Financial
High
Market
Medium
Competitive
Medium
Execution
Medium
Regulatory
Low
Red Flags
- ⚠
Cash balance ($11.6M) is critically low relative to annual net loss ($14.0M), indicating high cash burn.
- ⚠
Persistent GAAP net losses without a clear, near-term path to profitability.
- ⚠
Uncertainty around the timing and terms of future capital raises to sustain operations.
Upcoming Risk Events
- 📅
Q1 2026 earnings miss or weak forward guidance
- 📅
Failure to secure adequate funding within the next 6-9 months
- 📅
Increased competitive pressure from new non-invasive therapies
When to Reconsider
- 🚪
Failure to announce a significant capital raise by Q3 2026.
- 🚪
Cash balance falling below $5 million without a clear funding plan.
- 🚪
Quarterly revenue growth decelerates below 15% YoY for two consecutive quarters.
Unlock ECOR Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does electroCore, Inc. (ECOR) Do?
Market Cap
$52.85M
Sector
Healthcare
Industry
Medical Devices
Employees
73
electroCore, Inc., a bioelectronic medicine and general wellness company, provides non-invasive vagus nerve stimulation (nVNS) technology platform in the United States, the United Kingdom, and internationally. The company develops gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also develops Truvaga 350, a personal use consumer electronics general wellness product and Truvaga Plus, an, app-enabled general wellness product. It also offers non-invasive bioelectronic therapies for the treatment of chronic pain and wellness conditions. In addition, the company offers TAC-STIM for human performance and gammaCore Sapphire, a portable, reusable, rechargeable, and reloadable prescription medical device for various primary headache conditions. electroCore, Inc. was incorporated in 2005 and is headquartered in Rockaway, New Jersey.
Visit electroCore, Inc. WebsiteInvestment Thesis
electroCore presents a high-risk, high-reward opportunity given its innovative, FDA-approved gammaCore device addressing a significant market for headache disorders with strong revenue growth and gross margins. However, its severe financial distress and reliance on future funding make it a highly speculative investment. Success hinges on a timely and favorable capital raise to bridge the gap to profitability and unlock its market leadership potential.
Is ECOR Stock Undervalued?
Unlock the full AI analysis for ECOR
Get the complete DVR score, risk analysis, and more
ECOR Price Targets & Strategy
12-Month Target
$12.00
Bull Case
$18.00
Bear Case
$3.00
Valuation Basis
Based on a forward P/S multiple of 3x applied to a projected FY2026 revenue of ~$41.6M (assuming 30% YoY growth from FY2025), resulting in an estimated market cap of ~$124.8M divided by ~7.06M shares.
Entry Strategy
Given high financial risk, dollar-cost average on significant dips, ideally below $6.00, only for aggressive portfolios. Await clear signs of funding resolution.
Exit Strategy
Take profit at $12.00-$15.00 range; consider full exit if financial health deteriorates further or new funding is highly dilutive. Stop loss at $4.50.
Portfolio Allocation
1-3% for aggressive risk tolerance only.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is ECOR Financially Healthy?
Valuation
P/E Ratio
-3.83
Profitability
Gross Margin
87.00%
Return on Equity
-447.87%
Revenue Growth
27.00%
EPS
$-1.65
Balance Sheet
Cash & Equivalents
$11.60M
Cash Flow
EBITDA
-$8.70M
Other
Beta (Volatility)
0.48
Does ECOR Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
2 Identified
The moat is primarily built on its intellectual property and regulatory approvals, which create significant barriers to entry. The recent expansion of its IP portfolio further strengthens this. However, the durability is limited by the potential for new, superior technologies or a large pharmaceutical/med-tech company to develop a competitive offering.
Moat Erosion Risks
- •Expiration of key patents or successful challenges to IP.
- •Development of more effective, cheaper, or easier-to-use alternative therapies.
- •Lack of sufficient capital to defend IP or accelerate market adoption against larger competitors.
ECOR Competitive Moat Analysis
Sign up to see competitive advantages
ECOR Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral (Mixed signals: compelling product vs. significant financial challenges)
Institutional Sentiment
Positive (HC Wainwright reiterated Buy rating with an $18 price target post-FY2025 results).
Insider Activity (Form 4)
CEO Dan Goldberger's retirement was effective April 1, 2026 (no associated transaction). Inducement grants under NASDAQ Rule 5635(c)(4) were made on April 8, 2026 (likely to new executives/hires, details unspecified). No specific open market buys or sells by CEO/CFO flagged.
Options Flow
Normal options activity (no specific data provided to indicate otherwise).
Earnings Intelligence
Next Earnings
2026-05-06
Surprise Probability
Medium
Historical Earnings Pattern
Not enough specific historical data on price reaction provided to establish a consistent pattern, though Q4 2025 EPS beat estimates.
Key Metrics to Watch
Competitive Position
Top Competitor
Not specified in real-time intelligence; general competitors in pain management or non-invasive neuromodulation exist.
Market Share Trend
Not specified, but revenue growth indicates expanding adoption.
Valuation vs Peers
Trading at a negative TTM P/E (-3.68x) due to losses. P/S ratio of ~1.5x (based on current MC and FY25 rev) is low for a medical device company with high gross margins and growth potential, but reflects financial risk.
Competitive Advantages
- •Patented, FDA-approved gammaCore non-invasive vagus nerve stimulator (nVNS) technology.
- •High gross margins (86-87%) indicate strong product value and cost efficiency.
- •Addresses a large and underserved market for headache disorders with a non-pharmacological solution.
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive ECOR Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings Report (expected May 6, 2026)
- •Announcement of successful capital raise or debt financing
- •Significant new partnership or distribution agreement
Medium-Term (6-18 months)
- •Acceleration of revenue growth above 30% YoY
- •Expansion into new therapeutic indications for gammaCore
- •Improved reimbursement coverage reducing patient out-of-pocket costs
Long-Term (18+ months)
- •Establishment as a market leader in non-invasive neuromodulation for chronic pain
- •Disruption of traditional pharmacological treatments for headache disorders
- •Leveraging expanded IP for novel device developments
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for ECOR?
- ✓
Announcement of a non-dilutive or minimally dilutive funding round.
- ✓
Acceleration in quarter-over-quarter revenue growth and progress towards positive operating cash flow.
- ✓
Successful commercial expansion and favorable reimbursement developments.
Bull Case Analysis
See what could go right with Premium
Competing with ECOR
See how electroCore, Inc. compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
electroCore, Inc. ECOR | $52.9M | 2.0 | -3.8 | $32.0M | 0.0% | 27.0% | |
AbbVie Inc ABBV | $403.8B | 0.1 | 171.8 | — | — | — | Compare → |
Johnson & Johnson JNJ | — | 1.0 | — | — | — | — | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $161.1B | 0.2 | 20.2 | $17.6B | 12.4% | -1.7% | Compare → |
UnitedHealth Group Inc UNH | $300.6B | 0.5 | 17.3 | — | — | — | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How electroCore, Inc. Makes Money
electroCore, Inc. develops and commercializes gammaCore, a unique, non-invasive, handheld medical device that uses mild electrical stimulation to modulate the vagus nerve in the neck. This device is FDA-approved for the acute and preventative treatment of certain primary headache disorders, including migraine and cluster headaches. The company generates revenue by selling or leasing these prescription-based devices and associated components to patients (through healthcare providers), clinics, and healthcare systems, offering a drug-free alternative for pain management.
Read Full Business Model BreakdownFAQ
What is the DVR Score for electroCore, Inc. (ECOR)?
As of April 10, 2026, electroCore, Inc. has a DVR Score of 2.0 out of 10, placing it in the "Risk Trap" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of electroCore, Inc.?
electroCore, Inc.'s market capitalization is approximately $52.9M. The company operates in the Healthcare sector within the Medical Devices industry.
What ticker symbol does electroCore, Inc. use?
ECOR is the ticker symbol for electroCore, Inc.. The company trades on the NCM.
What is the risk level for ECOR stock?
Our analysis rates electroCore, Inc.'s overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of ECOR?
electroCore, Inc. currently has a price-to-earnings (P/E) ratio of -3.8. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Is electroCore, Inc.'s revenue growing?
electroCore, Inc. has reported revenue growth of 27.0%. The company is showing strong top-line momentum.
Is ECOR stock profitable?
electroCore, Inc. has a profit margin of 0.0%. The company is currently unprofitable.
How often is the ECOR DVR analysis updated?
Our AI-powered analysis of electroCore, Inc. is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 10, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for ECOR (electroCore, Inc.) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.